Navigation Links
Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Date:1/28/2009

PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for a separate Lamotrigine product, Lamotrigine Tablets Chewable Dispersible (CD).

Mylan Pharmaceuticals' and Genpharm's ANDAs were approved for the 25 mg, 100 mg, 150 mg and 200 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) Tablets. This product had annual U.S. sales of approximately $2.5 billion for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

Genpharm's ANDA was approved for the 5 mg and 25 mg strengths of the generic version of GlaxoSmithKline's Lamictal(R) CD Tablets. This product had annual U.S. sales of approximately $91 million for the 12 months ending Sept. 30, 2008, for the same strengths according to IMS Health.

These products are used for the treatment of epilepsy and for maintenance treatment of bipolar I disorder. Mylan will distribute both products immediately and under the Mylan Pharmaceuticals label.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
2. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
3. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
5. Mylan Announces Move to NASDAQ Stock Market
6. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
7. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
8. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
11. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology: